Insulin Glargine gives New Hope for those with Type-2 Diabetes in New Clinical Trials

Insulin Glargine CAS# 160337-95-1:

Insulin GlargineInsulin Glargine is basically used as a treatment for Type-1 diabetes, a condition in which the body is not able to produce enough insulin, and as a result, is unable to control the amount of sugar in the blood stream. It is also used for the treatment of Type-2 diabetes where the body is unable to use insulin normally. Insulin Glargine is a synthetic version of insulin which is long lasting and works by replacing the insulin which is naturally produced by the body in order to move sugar from the blood to other parts of the body, where it is stored and used for energy.

In recent clinical trials, a fixed ratio combination of Insulin Glargine along with Lixisenatide, which is a GLP-1 RA was shown to have superior reduction in the average blood glucose levels as compared to past clinical trials. Overall, the fixed ratio combination showed to have a safety profile which reflected those of insulin Glargine and Lixisentide. According to the researchers, the meeting of the primary objectives of this clinical trial showcases the clinical value of Insulin Glargine. The study is said to be completed by Q3 of 2015. Read Article

Saxagliptin Hydrochloride- The Most Efficient Substitute for Insulin

Saxagliptin hydrochloride CAS: 709031-78-7

The Hyderabad-based pharmaceutical company, Lee Pharma, has recently released a statement which says that Saxagliptin hydrochloride is the most effective substitute for insulin injectables for the treatment of Type-2 diabetes.

The statement was made while Lee Pharma said that the multinational company AstraZeneca, which it applied to for the patented diabetes medication Saxagliptin hydrochloride, was unable to keep up with the demand for the patented medicine. According to reports, Lee Pharma, which is a Rs. 200 crore drug company, filed an application back in June with the Controller of Patents in Mumbai seeking the license which is compulsory for the use of Saxagliptin hydrochloride.

Lee Pharma said the reason for filing the application and the growing need for Saxagliptin hydrochloride is that the population of Type-2 diabetes in India is currently around 60 million, and there were only four key anti-diabetes medications being used with Saxagliptin hydrochloride being one of them. The spokesperson from Lee Pharma also added that if one million patients were to be prescribed Saxagliptin, it would require the manufacturer to roll out around 365 million tablets each year to keep up with the demand. Currently, Lee Pharma has three major manufacturing units in Visakhapatnam and Hyderabad. The anti-diabetic medication they manufacturer is sold both locally and is also exported to 48 countries around the world.

As suppliers/distributors, LGM Pharma can assist you in acquiring Saxagliptin Hydrochloride CAS# 945667-22-1 to carry out your clinical trials, or for new formulation of dosages. We offer our customers the best premium quality APIs, with full compliance to strict guidelines and regulated by leading authorities. Apart from that, our customers also get our expert support throughout the R&D process.

General Drug Facts

Saxagliptin hydrochloride is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is commonly used for the treatment of Type-2 diabetes. It works by increasing insulin levels that are released by your body, while decreasing the amount of sugar made by the natural process in a person’s body. The drug is usually used alongside a proper diet and exercise. Saxagliptin hydrochloride can be used alone and along with other medication.

General Disease Facts

Type-2 diabetes is a chronic disease in which a person has a high level of sugar in their blood. Type-2 diabetes is one of the most common forms of diabetes and effects more people worldwide than Type-1 diabetes. Type-2 diabetes can also develop in those people who are underweight, although it usually occurs in the elderly.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

 

Linagliptin Could be the Answer to Macrovascular Complications Type-2 Diabetics

linagliptinA new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals.

According to reports, the cardiovascular outcome trials using Linagliptin are currently being carried out and it will take a few years before the results are available. However, one well-known cardiovascular surrogate parameter is endothelial dysfunction. Research has shown that endothelial dysfunction is present in patients with early diabetes and can be improved with the help of pharmacological interventions. According to the researchers, the surrogate measurement could prove to be helpful in getting a better understanding of the cardiovascular effects of Linagliptin.

UKPDS (United Kingdom Prospective Diabetes Study) post trial monitoring highlighted the importance of an early glucose lowering intervention in patients with T2DM with respect to micro- and macrovascular complications. The aim of the study has been to further investigate the effects of Linagliptin in coronary patients who have Type-2 diabetes on cardiovascular surrogate measurements along with mechanical and biochemical endothelial assessments.

As the top suppliers of API products for the research and development of anti-diabetic drugs, LGM Pharma supplies high quality Linagliptin CAS# 668270-12-0 for future drug development studies.

General Drug Facts

Linagliptin is used along with a suitable diet and exercise program and sometimes along with other medications to control high blood sugar levels. It is normally used by those people who have been diagnosed with Type-2 diabetes. Controlling high blood sugar is important since it prevents kidney damage, nerve problems, blindness and a loss of function of limbs. Results in 2010 from a Phase III clinical trial of Linagliptin showed that it is highly effective when it comes to reducing blood sugar levels.

General Disease Facts

Type 2 diabetes is common among middle-aged and older adults, but it has also been found in younger people too. Type-2 diabetes is characterized by a high blood glucose level which is caused by either the body’s inability to use insulin properly or the lack of insulin in the body.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Exenatide Capsule Gleans Patent in Israel

Exenatide AcetateKnown as the brand name Byetta in the United States, which is marketed by AstraZeneca, Exenatide is a GLP-1 analog that is currently offered as an injectable treatment for type 2 diabetes. In mid-January 2015 Oramed Pharmaceuticals was granted a patent in Israel for the oral administration of Exenatide. As an effectual therapy for patients with type 2 diabetes, the advent of this Exenatide capsule is exciting for both patients and practitioners. Exenatide works by producing insulin release at increased glucose levels, which creates a feeling of satiety in patients, subsequently causing a reduction in food intake. This extra bonus of eliciting a reduction in dietary consumption makes Exenatide an ideal treatment for weight loss and weight control, as well as for insulin control. The injectable form of Exenatide has been helpful for patients, but challenging in terms of medication adherence. Many patients dislike using an injectable form of medication daily, so the novel Exenatide capsule is sure to create an optimal form of administration.

Exenatide is also being examined as a potential therapy for patients with Parkinson’s disease. In May 2014 a “Proof of Concept” trial was shared from the Sobell Department of Motor Neuroscience at the UCL Institute of Neurology in London. Basing patient results on a year’s worth of sound data from patients with Parkinson’s disease who had been administered Exenatide for a full year (May 2013-May 2014), an analysis of data showed noteworthy improvements in patients who received Exenatide. Researchers involved in this study cite the neuroprotective benefits of Exenatide, particularly for neuroplasticity. The side effect profile of Exenatide is also a plus for patients, with a small minority of trial participants experiencing mild nausea. The aforementioned study involved 44 patients with moderate to severe Parkinson’s disease. Approximately 20 of the patients received Exenatide in addition to their usual best in care treatment program, and 24 patients were given the placebo alongside best in care therapy. At the one year mark significantly clinical differences were apparent between the groups, with meaningful motor and cognitive differences gleaned from the patients group who received Exenatide. Even at the 14 month mark, when patients who had received Exenatide were taking a holiday from this medication the differences were still widely apparent between both the groups. Researchers utilized the Mattis Dementia Rating scale, as well as a blinded MDS-UPDRS motor subscale evaluation for the patients. The participants who were administered Exenatide had advantages of 5.6 on the blinded MDS-UPDRS motor subscale and 5.3 points on the Mattis Dementia Rating scale as compared to the placebo group. This information is hopeful for the future use of Exenatide for the treatment of not only type 2 diabetes, but also potentially for patients with Parkinson’s disease.

Whether it is injectable or oral Exenatide, LGM Pharma is available to assist clients as a supplier/distributor of the Exenatide CAS# 141758-74-9 API or the Exenatide Acetate CAS# 141732-76-5 API for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Canagliflozin Continues to be a Viable Treatment for Type 2 Diabetes

hemoglobin a1cOn January 16, 2015 the Journal of Diabetes and its Complications shared positive findings from a recent post hoc analysis of Canagliflozin. Comprehensive data was analyzed from Phase 3 studies of Canagliflozin in adult patients with type 2 diabetes. This placebo-controlled study was comprised of four 26 week periods, with changes in HbA1c being sought by the end of each 26 week segment. Canagliflozin proved to be successful in lowering the HbA1c of the participants as well as showing overall glycemic improvements. Dosages of 100 milligrams and 300 milligrams of Canagliflozin elicited significantly greater reductions in HbA1c as compared to the patients who were administered a placebo. Additionally, patients tolerated Canagliflozin well and the safety profile of this anti diabetic therapy was tangible. As an effectual sodium glucose co–transporter 2 inhibitor Canagliflozin has performed remarkably in a vast number of studies over the last decade.

Another recent article focused on the positive effects of Canagliflozin, published in the January 20, 2015 issue of Diabetes, Obesity & Metabolism. The information disseminated revealed a sizable reduction on serum uric acid in patients with type 2 diabetes mellitus who were given Canagliflozin in studies. An increase in uric acid, also known as Hyperuricaemia can often lead to complications from type 2 diabetes, such as kidney stones and gout. Information gleaned from four Phase 3 studies showed a reduction of 13 percent on serum uric acid levels for patients who were administered Canagliflozin, as compared to a placebo. The reduction was apparent at week 26 of the studies on average, and patients who saw these reductions also experienced a major decrease of incidences with gout and kidney stones. Of the patients who received 100 milligrams of Canagliflozin 23.5 percent of these participants saw a viable reduction in serum uric acid levels. Approximately 32.4 percent of participants who were dosed with 300 milligrams daily of Canagliflozin experienced a worthy reduction in serum uric acid levels. Patients in the placebo group had a mere 3.1 percent reduction in their uric acid levels at the 26 week mark.

canagliflozinKnown as the brand name Invokana, which is marketing by Janssen, Canagliflozin is an oral medication used to treat type 2 diabetes. Patients with type 1, or juvenile diabetes, should not take Canagliflozin. In addition to diet and exercise Canagliflozin has shown to be a safe and effective treatment for adult patients with type 2 diabetes who cannot control their glucose levels. Canagliflozin is typically taken once daily by mouth. Adverse effects are uncommon, with most commonly reported side effects being nausea, constipation and frequent urination. LGM Pharma can assist clients as a supplier/distributor of the API Canagliflozin, CAS # 842133-18-0, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.